by Martin J Boeree, Norbert Heinrich, Rob Aarnoutse et al.
Lancet Infect Dis 2016, Published Online: October 26, 2016
Tuberculosis is the world’s leading infectious disease killer. The authors aimed to identify shorter, safer drug regimens for the treatment of tuberculosis. They conclude that a dose of 35 mg/kg rifampicin was safe, reduced the time to culture conversion in liquid media, and could be a promising component of future, shorter regimens. Their adaptive trial design was successfully implemented in a multi-centre, high tuberculosis burden setting, and could speed regimen development at reduced cost.